Abbott Attempted to Terminate Merger With Alere | GenomeWeb

NEW YORK (GenomeWeb) – Abbott Laboratories attempted to terminate its pending merger with Alere, Alere said late on Thursday. 

The firm has twice delayed filing its 2015 earnings report, leading Abbott to inform Alere that "it has serious concerns about, among other things, the accuracy of various representations, warranties and covenants made by Alere in the parties' merger agreement," Alere said. Abbott even offered to pay Alere a termination fee of $30 million to $50 million to pay for Alere's transaction expenses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.